A detailed history of Sg Americas Securities, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 22,945 shares of NRIX stock, worth $432,283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,945
Previous 103,199 77.77%
Holding current value
$432,283
Previous $2.15 Million 76.04%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$18.93 - $25.69 $1.52 Million - $2.06 Million
-80,254 Reduced 77.77%
22,945 $516,000
Q2 2024

Jul 12, 2024

BUY
$12.02 - $21.3 $973,680 - $1.73 Million
81,005 Added 364.99%
103,199 $2.15 Million
Q1 2024

May 06, 2024

SELL
$7.77 - $15.66 $34,242 - $69,013
-4,407 Reduced 16.57%
22,194 $326,000
Q4 2023

Jan 12, 2024

BUY
$4.25 - $10.71 $25,338 - $63,853
5,962 Added 28.89%
26,601 $275,000
Q3 2023

Oct 13, 2023

BUY
$7.86 - $10.08 $162,222 - $208,041
20,639 New
20,639 $162,000
Q1 2023

Apr 28, 2023

BUY
$8.56 - $13.26 $2,996 - $4,641
350 Added 1.5%
23,725 $211,000
Q4 2022

Feb 02, 2023

SELL
$9.86 - $14.59 $4,910 - $7,265
-498 Reduced 2.09%
23,375 $257,000
Q3 2022

Oct 31, 2022

SELL
$12.33 - $19.81 $127,590 - $204,993
-10,348 Reduced 30.24%
23,873 $311,000
Q2 2022

Jul 29, 2022

BUY
$7.88 - $14.82 $269,661 - $507,155
34,221 New
34,221 $434,000
Q1 2022

Apr 29, 2022

SELL
$12.94 - $29.65 $188,911 - $432,860
-14,599 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$26.43 - $34.5 $277,329 - $362,008
-10,493 Reduced 41.82%
14,599 $423,000
Q3 2021

Nov 01, 2021

BUY
$22.71 - $36.69 $365,494 - $590,488
16,094 Added 178.86%
25,092 $752,000
Q2 2021

Aug 12, 2021

BUY
$24.21 - $35.89 $36,411 - $53,978
1,504 Added 20.07%
8,998 $239,000
Q1 2021

May 13, 2021

BUY
$26.98 - $50.17 $202,188 - $375,973
7,494 New
7,494 $233,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $888M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.